286 related articles for article (PubMed ID: 22647972)
21. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.
Giampieri R; Scartozzi M; Del Prete M; Maccaroni E; Bittoni A; Faloppi L; Bianconi M; Cecchini L; Cascinu S
Crit Rev Oncol Hematol; 2013 Nov; 88(2):272-83. PubMed ID: 23806981
[TBL] [Abstract][Full Text] [Related]
22. EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.
Loupakis F; Vasile E; Santini D; Masi G; Falcone A; Graziano F
Pharmacogenomics; 2008 Jan; 9(1):55-69. PubMed ID: 18154448
[TBL] [Abstract][Full Text] [Related]
23. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors.
Clarke SJ; Karapetis CS; Gibbs P; Pavlakis N; Desai J; Michael M; Tebbutt NC; Price TJ; Tabernero J
Crit Rev Oncol Hematol; 2013 Feb; 85(2):121-35. PubMed ID: 22762963
[TBL] [Abstract][Full Text] [Related]
24. Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.
Dienstmann R; Salazar R; Tabernero J
Am Soc Clin Oncol Educ Book; 2015; ():e149-56. PubMed ID: 25993166
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS.
Liu J; Hu J; Cheng L; Ren W; Yang M; Liu B; Xie L; Qian X
Onco Targets Ther; 2016; 9():557-65. PubMed ID: 26869800
[TBL] [Abstract][Full Text] [Related]
26. The role of tumor markers and biomarkers in colorectal cancer.
Lech G; Slotwinski R; Krasnodebski IW
Neoplasma; 2014; 61(1):1-8. PubMed ID: 24195503
[TBL] [Abstract][Full Text] [Related]
27. New and potential clinical applications of KRAS as a cancer biomarker.
Kriegshäuser G; Auner V; Zeillinger R
Expert Opin Med Diagn; 2010 Sep; 4(5):383-95. PubMed ID: 23496197
[TBL] [Abstract][Full Text] [Related]
28. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
[TBL] [Abstract][Full Text] [Related]
29. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.
Malapelle U; Carlomagno C; de Luca C; Bellevicine C; Troncone G
J Clin Pathol; 2014 Jan; 67(1):1-9. PubMed ID: 24022727
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer.
Sobani ZA; Sawant A; Jafri M; Correa AK; Sahin IH
World J Clin Oncol; 2016 Oct; 7(5):340-351. PubMed ID: 27777877
[TBL] [Abstract][Full Text] [Related]
31. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.
Stintzing S; Stremitzer S; Sebio A; Lenz HJ
Hematol Oncol Clin North Am; 2015 Feb; 29(1):43-60. PubMed ID: 25475572
[TBL] [Abstract][Full Text] [Related]
32. Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.
Spano JP; Milano G; Vignot S; Khayat D
Crit Rev Oncol Hematol; 2008 Apr; 66(1):21-30. PubMed ID: 18206383
[TBL] [Abstract][Full Text] [Related]
33. RNA biomarkers in colorectal cancer.
Bustin SA; Murphy J
Methods; 2013 Jan; 59(1):116-25. PubMed ID: 23079397
[TBL] [Abstract][Full Text] [Related]
34. Personalizing therapy for colorectal cancer.
Wong A; Ma BB
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):139-44. PubMed ID: 24025538
[TBL] [Abstract][Full Text] [Related]
35. Multigene assays in metastatic colorectal cancer.
Deeb KK; Sram JP; Gao H; Fakih MG
J Natl Compr Canc Netw; 2013 Sep; 11 Suppl 4():S9-17. PubMed ID: 24158971
[TBL] [Abstract][Full Text] [Related]
36. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives.
Custodio A; Barriuso J; de Castro J; Martínez-Marín V; Moreno V; Rodríguez-Salas N; Feliu J
Cancer Treat Rev; 2013 Dec; 39(8):908-24. PubMed ID: 23510598
[TBL] [Abstract][Full Text] [Related]
37. Personalized treatment for advanced colorectal cancer: KRAS and beyond.
Patel GS; Karapetis CS
Cancer Manag Res; 2013; 5():387-400. PubMed ID: 24294007
[TBL] [Abstract][Full Text] [Related]
38. Personalized treatment for patients with colorectal cancer: role of biomarkers.
Duffy MJ
Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
[TBL] [Abstract][Full Text] [Related]
39. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
Rankin A; Klempner SJ; Erlich R; Sun JX; Grothey A; Fakih M; George TJ; Lee J; Ross JS; Stephens PJ; Miller VA; Ali SM; Schrock AB
Oncologist; 2016 Nov; 21(11):1306-1314. PubMed ID: 27682134
[TBL] [Abstract][Full Text] [Related]
40. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.
Zhai Z; Yu X; Yang B; Zhang Y; Zhang L; Li X; Sun H
Semin Cell Dev Biol; 2017 Apr; 64():107-115. PubMed ID: 27578007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
